Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 20, 2026Biomedicine & PharmacotherapyOpen Access

A six-proline stabilized trimeric spike DNA vaccine induces robust immunity and protects against SARS-CoV-2 delta challenge in K18-hACE2 transgenic mice

View Full Paper
Ask AI
Bookmark
Share

Authors

AGAytül GülCGCeren GülTKTuğba Karakavuk

Discussion

Loading...

Member takes

Overview

Randomized trial shows robust immunity from a DNA vaccine in mice, highlighting its potential for emerging variants.

Key Points

  • This study aims to evaluate the immunogenicity and protective efficacy of a DNA vaccine targeting the SARS-CoV-2 Delta variant.
  • DNA vaccine encoding six-proline stabilized trimeric spike protein administered via intramuscular and intradermal injection with electroporation.
  • Immunogenicity assessed by measuring anti-S1 IgG titers and neutralizing antibodies in BALB/c mice.
  • Protection tested in K18-hACE2 transgenic mice during lethal virus challenge.
  • High anti-S1 IgG titers observed: ∼22,000 for IM and ∼83,000 for ID+EP.
  • In a lethal challenge model, vaccination conferred 77.7% protection with no detectable viral load.
  • Elevated neutralizing antibody titers of 194.01 for IM and 337.79 for ID+EP, indicating strong immune response.

Cite This Study

Gül et al. (2026) studied this question.

synapsesocial.com/papers/6a362de1db0793dc1a535edehttps://doi.org/10.1016/j.biopha.2026.119679
View Full Paper
Ask AI
Bookmark
Share